- Home
- UBSI vs AXSM Comparison
UBSI vs AXSM Comparison
Compare UBSI & AXSM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UBSI
- AXSM
- Stock Information
- Founded
- UBSI 1982
- AXSM 2012
- Country
- UBSI United States
- AXSM United States
- Employees
- UBSI N/A
- AXSM N/A
- Industry
- UBSI Major Banks
- AXSM Biotechnology: Pharmaceutical Preparations
- Sector
- UBSI Finance
- AXSM Health Care
- Exchange
- UBSI Nasdaq
- AXSM Nasdaq
- Market Cap
- UBSI 5.3B
- AXSM 5.1B
- IPO Year
- UBSI N/A
- AXSM 2015
- Fundamental
- Price
- UBSI $38.41
- AXSM $105.44
- Analyst Decision
- UBSI Hold
- AXSM Strong Buy
- Analyst Count
- UBSI 4
- AXSM 17
- Target Price
- UBSI $40.13
- AXSM $171.65
- AVG Volume (30 Days)
- UBSI 905.9K
- AXSM 649.3K
- Earning Date
- UBSI 07-24-2025
- AXSM 08-04-2025
- Dividend Yield
- UBSI 3.85%
- AXSM N/A
- EPS Growth
- UBSI 2.88
- AXSM N/A
- EPS
- UBSI 2.70
- AXSM N/A
- Revenue
- UBSI $1,021,155,000.00
- AXSM $432,157,000.00
- Revenue This Year
- UBSI $20.44
- AXSM $62.84
- Revenue Next Year
- UBSI $5.18
- AXSM $60.02
- P/E Ratio
- UBSI $14.25
- AXSM N/A
- Revenue Growth
- UBSI 0.82
- AXSM 72.16
- 52 Week Low
- UBSI $30.51
- AXSM $72.21
- 52 Week High
- UBSI $44.43
- AXSM $139.13
- Technical
- Relative Strength Index (RSI)
- UBSI 65.26
- AXSM 47.99
- Support Level
- UBSI $36.27
- AXSM $102.26
- Resistance Level
- UBSI $36.88
- AXSM $106.35
- Average True Range (ATR)
- UBSI 0.70
- AXSM 3.09
- MACD
- UBSI 0.22
- AXSM 0.15
- Stochastic Oscillator
- UBSI 99.33
- AXSM 66.44
About UBSI United Bankshares Inc.
United Bankshares Inc is a financial holding company that provides banking services. The company operates in one segment: Community banking, which accepts deposits, makes loans (for personal, credit card, commercial, and construction uses), provides brokerage services, safe deposit boxes, and related services.
About AXSM Axsome Therapeutics Inc.
Axsome Therapeutics Inc is a clinical-stage biopharmaceutical company. It is engaged in developing novel therapies for the management of the central nervous system, or CNS, disorders for which there are limited treatment options. Its pipeline products includes AXS-05, AXS-07, AXS-12, and AXS-14. It manages its business as one operating segment and reporting unit, which is the business of developing and delivering novel therapies for the management of CNS disorders.